RxDoctor Payments Data

Jennifer Callard

Family · Georgetown, DENPI 1437547106

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 674 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,692in general payments, 2019–2025

Across 674 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$832
  • Johnson & Johnson$818
  • Lilly USA, LLC$747
  • Pfizer$687
  • plus $7K from 48 others

What the payments were for

  • Food & beverage$12,692100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,692 in reported general payments places this provider in the 95th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide113$165,731
JardianceEmpagliflozin99$118,012
EliquisApixaban52$58,657
RybelsusSemaglutide30$50,512
FarxigaDapagliflozin Propanediol30$47,082
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$36,605
JanuviaSitagliptin Phosphate21$30,161
VivitrolNaltrexone Microspheres17$29,148
MyrbetriqMirabegron20$19,478
LinzessLinaclotide23$18,915
TradjentaLinagliptin21$16,953
Bevespi AerosphereGlycopyrrolate/Formoterol Fum18$14,705
XareltoRivaroxaban12$14,342
Tresiba Flextouch U-100Insulin Degludec11$7,848
Albuterol Sulfate HfaAlbuterol Sulfate129$4,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,048$216,243143 claims
Boehringer IngelheimJardiance, Tradjenta$467$134,965120 claims
AstraZenecaFarxiga, Bevespi Aerosphere$832$61,78748 claims
PfizerEliquis$687$58,65752 claims
GSKTrelegy Ellipta$677$36,60521 claims
MerckJanuvia$413$30,16121 claims
Alkermes, Inc.Vivitrol$14$29,14817 claims
Astellas Pharma US IncMyrbetriq$290$19,47820 claims
AbbVieLinzess$1,629$18,91523 claims
Johnson & JohnsonXarelto$818$14,34212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 523 family providers in Delaware.

Other family in Georgetown

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →